Last reviewed · How we verify
P1101 270µg Q1W, 48 doses — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
P1101 270µg Q1W, 48 doses (P1101 270µg Q1W, 48 doses) — PharmaEssentia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| P1101 270µg Q1W, 48 doses TARGET | P1101 270µg Q1W, 48 doses | PharmaEssentia | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- P1101 270µg Q1W, 48 doses CI watch — RSS
- P1101 270µg Q1W, 48 doses CI watch — Atom
- P1101 270µg Q1W, 48 doses CI watch — JSON
- P1101 270µg Q1W, 48 doses alone — RSS
Cite this brief
Drug Landscape (2026). P1101 270µg Q1W, 48 doses — Competitive Intelligence Brief. https://druglandscape.com/ci/p1101-270-g-q1w-48-doses. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab